Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety and Pharmacokinetics of NNC0519-0130 Once Weekly s.c. Versussemaglutide 1.0 mg and Placebo in People With Chronic Kidney Disease, With or Without Type 2 Diabetes, and With Overweight or Obesity: a Proof-of-concept and Dose-finding Study

NCT06717698 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06717698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06717698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety and Pharmacokinetics of NNC0519-0130 Once Weekly s.c. Versussemaglutide 1.0 mg and Placebo in People With Chronic Kidney Disease, With or Without Type 2 Diabetes, and With Overweight or Obesity: a Proof-of-concept and Dose-finding Study
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Recruiting
Start date
December 2, 2024
Completion date
September 17, 2026
Enrollment
465 (estimated)
Sites
147

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease